The most dangerous phrase in our language is “we have always done it this way”

In lupus nephritis (LN), “activity” gets the spotlight—but chronic scarring often decides the long game. So: which chronicity score best predicts outcomes—NIH Chronicity Index (NIH-CI) or the Mayo Clinic Chronicity Score (MCCS)? buff.ly/tvebmPZ

🫁 ERS/EULAR 2026 CTD-ILD Guidelines — Key Takeaways 🔹 Covers SSc, RA, IIM, Sjögren, SLE & MCTD–ILD 🔹 Built on 25 PICO 28 narrative questions using GRADE methodology 📌 Screening 👉 HRCT = gold standard 🚫 Do NOT replace HRCT with PFTs or lung ultrasound (high miss rates) ✅ Screen ALL SSc & MCTD ✅ Screen RA / SjD / IIM if risk factors present 📌 Baseline risk assessment Assess globally using: • HRCT extent/pattern • FVC DLCO • Autoantibodies • CRP/ESR • Clinical severity 📌 Monitoring 🔁 PFTs every 3–6 months initially, then 6–12 monthly 🔁 HRCT: • SSc/RA: every 1–2 yrs • IIM (high-risk): as early as 3–6 months 📌 Treatment recommendations 🟢 SSc-ILD • Tocilizumab (strong) • MMF / Rituximab / Cyclophosphamide (conditional) • Nintedanib for progressive fibrosis • MMF Nintedanib combination allowed 🟢 IIM-ILD • Immunosuppression strongly recommended 🟢 RA / SjD / SLE / MCTD-ILD • Immunosuppressants suggested • RA-ILD (UIP): Pirfenidone may help 🟢 Progressive fibrosing CTD-ILD • Add Nintedanib 🚫 Lung biopsy NOT routine ✅ BAL only if infection / alternate dx suspected ✅ PROMs 6MWT for severity/prognosis ⸻ 🔥 TAKE-HOME MESSAGE Early HRCT screening structured monitoring timely immunosuppression/antifibrotics = cornerstone of CTD-ILD care. Missing ILD = missed survival opportunity. ⸻ 📄 Eur Respir J 2026 DOI: 10.1183/13993003.02533-2024 #CTDILD #InterstitialLungDisease #Rheumatology #Pulmonology #SystemicSclerosis #RA #Myositis #Sjogrens #SLE #ERS #EULAR #ILD #MedTwitter #RheumTwitter #PulmTwitter

Volver a México y compartir con colegas siempre es una alegría: colegas increíbles, preguntas buenísimas y mucha conversación. Gracias al Colegio Mexicano de Reumatología por la invitación. 🇲🇽

Call for new applicants for Rheum With a (re)View—a mentoring program focused on cultivating manuscript reviewers for the ACR’s 3 scientific journals. ACR/ARP members with research experience are encouraged to apply by March 31 ▶️ Details → rheumatology.org/acr-journal…

🆕 2025 ACR Guideline for Treatment of Systemic #Lupus Erythematosus 🦋 Just Released: Nov 3 #ACR25 🔥 🔸Review organ-specific treatment recommendations 🔸Steroid & HCQ Use Guidance ➠ Read the Full Guideline: acr.tw/47mkegj #RheumX #RheumTwitter #Rheum @RheumNow

Now published: The 2025 ACR Guideline for the Treatment of Systemic Lupus Erythematosus 📄 Read the paper: acr.tw/47mkegj ℹ️ See additional content and resources on this guideline at acr.tw/4mbHK4W

Thanks so much for this opportunity!! sites.libsyn.com/436041/lume…

Over 20 years have passed since the ACR last issued a broad treatment guideline for #SLE. In our NEWEST episode, Lisa R. Sammaritano, MD, summarizes the major updates in the soon-to-be-released 2025 guideline.🎙️LISTEN → acr.tw/4mTmpNi

#ESOC2025 🏃🏻‍♀️ESCAPE MEVO sub analysis 👉🏻 prognosis by image 🧠 👉🏻EVT <12 hs not > good functional outcome 👉🏻 Good collateral status > benefit 👉🏻 ⏱️<180 min > benefit

1/ 🧵The 2024 ACR Guidelines for Lupus Nephritis (LN) are here! Big shifts in screening, combo therapy, and steroid minimization. Let's break it down. Full text: acrjournals.onlinelibrary.wi…

Now published simultaneously in AC&R A&R, the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis See ACR guideline page for resources - rheumatology.org/lupus-guide… DOI link - doi.org/10.1002/acr.25528 Download the article - acr.tw/44sRwJM

Welcome Jaime! 🤩⭐️🤩⭐️

Rheumatologist when someone automatically calls an ANA ( ) “undifferentiated connective tissue disease”

NEW! Curious about how genetics influence autoimmune disease risk? Tune in & hear from @HocaogluMd, who dives into the study of antinuclear antibody production using data from the All of Us Research Program → acr.tw/42d7QN2 @ACR_Journals

🔟 Final Takeaways ✅ Obi improved renal outcomes in active LN ✅ Steroid-sparing effect (more Obi pts tapered to ≤7.5 mg/day) ✅ Proteinuria reduction = better long-term kidney survival ✅ Infections (esp. COVID-19) are a key safety concern

🚨 Breaking down the REGENCY trial 🚨 A Phase 3 RCT evaluating obinutuzumab (Obi) in lupus nephritis (LN). Let's dive into the study design, key findings, and the dosing regimens! 🧵⬇️

🚨 New Review Alert! 🚨 Dive into the evolving landscape of glucocorticoid therapy for lupus nephritis: 🔍 Historical shifts from high-dose to safer, low-dose strategies 🧬 Mechanisms, efficacy, & risks explored ⚖️ Balancing treatment efficacy with long-term safety

In a new summary of its 2024 Guideline for the Screening, Treatment, and Management of Lupus Nephritis, the ACR offers 41 recommendations for clinicians treating the condition. First author, Dr. Lisa Sammaritano, tells us more. #lupusnephritis

Usually everything from @drlalonares is quite interesting. This was not the exemption #ACR24